Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease

Circulation Journal

Volumn 72, Issue 12, 2008, Pages 1998-2003

  Miyazaki, Aya ^a   Ohuchi, Hideo ^a   Kurosaki, Ken Ichi ^a   Kamakura, Shiro ^a   Yagihara, Toshikatsu ^a   Yamada, Osamu ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Congenital heart disease (CHD); Sotalol; Tachyarrhythmia

Indexed keywords

AMIODARONE; APRINDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; FLECAINIDE; SOTALOL; VERAPAMIL;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; LOW DRUG DOSE; MALE; PULMONARY VALVE REPLACEMENT; RISK FACTOR; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; CARDIAC PACING, ARTIFICIAL; CARDIAC SURGICAL PROCEDURES; CATHETER ABLATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ELECTROCARDIOGRAPHY; FEMALE; HEART DEFECTS, CONGENITAL; HEART RATE; HUMANS; INFANT; MALE; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SOTALOL; TACHYCARDIA; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 56849121102     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0194     Document Type: Article

References (20)

1. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
2. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
3. Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, et al. Effects of antiarrhythmic drugs on in appropriate shocks in patients with implantable cardioverter defibrillators. Circ J 2008; 72: 102-105.
4. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks form implantable cardioverter defibrillators: The OPTIC study: A randomized trial. JAMA 2006; 295: 165-171.
5. MacNeil DJ. The side effect profile of class III antiarrhythmic drugs: Focus on d,l-sotalol. Am J Cardiol 1997; 80: 90G-98G.
6. Kodama I, Aizawa Y, Inoue H, Ohe T, Ogawa S, Okumura K, et al. Guidelines for drug treatment of arrhythmias (JCS 2004). Circ J 2004; 68(Suppl): 981-1053.
7. Maragnes P, Tipple M, Fournier A. Effectiveness of oral sotalol for treatment of pediatric arrhythimias. Am J Cardiol 1992; 69: 751-754.
8. Tanel RE, Walsh EP, Lulu JA, Saul JP. Sotalol for refractory arrhythmias in pediatric and young adult patients: Initial efficacy and long-term outcome. Am Heart J 1995; 130: 791-797.
9. Pfammatter JP, Paul T, Lehamann C, Kallfelz HS. Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 1995; 26: 1002-1007.
10. Beaufort-Krol GCM, Bink-Boelkens MTHE. Sotalol for atrial tachycardias after surgery for congenital heart disease. Pacing Clin Electrophysiol 1997; 20(Pt II): 2125-2129.
11. Benditt DG, Williams JG, Jin J, Deering TF, Zucker R, Browne K, et al. maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol 1999; 84: 270-277.
12. Kato K, Iinuma H, Inoue H, Ueda K, Ogawa S, Kasanuki H, et al. Clinical efficacy and safety of sotalol in treatment of patients with recurrent life-threatening ventricular tachyarrhythmias: Dose-finding study and long-term study by multi centre trials. J Clin Ther Med 1998; 14: 2603-2636.
13. Galik DM, Kim SG, Ferrick KJ, Roth JA, Fisher JD. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J 1997; 134: 155-160.
14. Smith TW, Cain ME. Class III antiarrhythmic drugs: Amiodarone, ibutilide, and sotalol. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology from cell to bedside, 4th edn. Philadelphia: WB Saunders; 2004; 932-941.
15. Chung MK, Schweikert RA, Wilkoff BL, Niebauer MJ, Pinski SL, Trohman RG, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of inhospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998; 32: 169-176.
16. Coumel P, Fidelle J, Loges-en-Jasas P. Amiodarone in the treatment of cardiac arrhythmias in children: One hundred thirty-five cases. Am Heart J 1980; 100: 1063-1069.
17. Garson A, Gillette PC, McVey P, Hesslein PS, Porter CBJ, Angell LK, et al. Amiodarone treatment of critical arrhythmias in children and young adults. J Am Coll Cardiol 1984; 4: 749-755.
18. Bucknall C, Keeton BR, Curry PVL, Tynan MJ, Sutherland GR, Holt D. Intravenous and oral amiodarone for arrhythmias in children. Br Heart J 1986; 56: 278-284.
19. Guccione P, Paul T, Garson A. Long-term follow-up of amiodarone therapy in the young: Continued efficacy, unimpaired growth, moderate side effects. J Am Coll Cardiol 1990; 15: 1118-1124.
20. Villian E. Amiodarone as treatment for atrial tachycardias after surgery. Pacing Clin Electrophysiol 1997; 20(Pt II): 2130-2132.